Reversible tobramycin-induced bilateral high-frequency vestibular toxicity.
We report an unusual case of tobramycin-induced bilateral high-frequency vestibular toxicity with subsequent clinical and objective evidence of functional recovery. In those patients with a clinical presentation suggestive of aminoglycoside-induced bilateral vestibular toxicity (ataxia and oscillopsia) and normal low-frequency (ENG-caloric) responses, high-frequency rotation chair testing should be performed to exclude a high-frequency vestibular deficit.
Walsh
R M
RM
Department of Otolaryngology, University Health Network, Toronto General Hospital, University of Toronto, Canada.
Bath
A P
AP
Bance
M L
ML
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D011552:Pseudomonas Infections; D020127:Recovery of Function; D014031:Tobramycin / Q000009:adverse effects*; D014724:Vestibular Function Tests; D014722:Vestibule, Labyrinth / Q000187:drug effects* / Q000503:physiopathology*
D000900:Anti-Bacterial Agents; D014031:Tobramycin